Zacks Research Issues Negative Forecast for CRL Earnings

Charles River Laboratories International, Inc. (NYSE:CRL) – Research analysts at Zacks Research dropped their Q3 2025 earnings per share (EPS) estimates for Charles River Laboratories International in a report issued on Wednesday, May 28th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings per share of $2.37 for the quarter, down from their previous forecast of $2.40. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $9.36 per share. Zacks Research also issued estimates for Charles River Laboratories International’s Q4 2025 earnings at $2.36 EPS, Q3 2026 earnings at $2.51 EPS and Q4 2026 earnings at $2.48 EPS.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, topping the consensus estimate of $2.06 by $0.28. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The business had revenue of $984.17 million during the quarter, compared to analyst estimates of $942.34 million. During the same period last year, the business posted $2.27 earnings per share. The company’s quarterly revenue was down 2.7% on a year-over-year basis.

CRL has been the subject of several other reports. TD Cowen raised Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $179.00 target price for the company in a research note on Wednesday, May 14th. Robert W. Baird boosted their target price on Charles River Laboratories International from $118.00 to $140.00 and gave the stock a “neutral” rating in a research note on Thursday, May 8th. Evercore ISI raised Charles River Laboratories International from an “in-line” rating to an “outperform” rating and set a $170.00 target price for the company in a research note on Thursday, May 8th. Citigroup raised Charles River Laboratories International from a “sell” rating to a “neutral” rating and boosted their target price for the stock from $155.00 to $175.00 in a research note on Tuesday, March 4th. Finally, Cowen raised Charles River Laboratories International from a “hold” rating to a “buy” rating in a research note on Wednesday, May 14th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating and four have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $171.85.

Charles River Laboratories International Trading Up 1.0%

CRL opened at $137.60 on Friday. Charles River Laboratories International has a 12 month low of $91.86 and a 12 month high of $254.15. The stock has a market capitalization of $6.76 billion, a price-to-earnings ratio of 917.33, a PEG ratio of 4.54 and a beta of 1.50. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. The business has a fifty day moving average price of $129.55 and a 200 day moving average price of $161.31.

Hedge Funds Weigh In On Charles River Laboratories International

Hedge funds have recently made changes to their positions in the company. Rothschild Investment LLC grew its holdings in shares of Charles River Laboratories International by 480.0% during the first quarter. Rothschild Investment LLC now owns 174 shares of the medical research company’s stock worth $26,000 after purchasing an additional 144 shares during the last quarter. Brooklyn Investment Group grew its holdings in shares of Charles River Laboratories International by 93.5% during the first quarter. Brooklyn Investment Group now owns 178 shares of the medical research company’s stock worth $27,000 after purchasing an additional 86 shares during the last quarter. HM Payson & Co. purchased a new position in shares of Charles River Laboratories International during the first quarter worth about $31,000. Optiver Holding B.V. purchased a new position in shares of Charles River Laboratories International during the fourth quarter worth about $37,000. Finally, GeoWealth Management LLC grew its holdings in shares of Charles River Laboratories International by 311.5% during the fourth quarter. GeoWealth Management LLC now owns 251 shares of the medical research company’s stock worth $46,000 after buying an additional 190 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Insiders Place Their Bets

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of the firm’s stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total transaction of $72,705.00. Following the transaction, the executive vice president now owns 19,513 shares of the company’s stock, valued at approximately $2,837,385.33. This trade represents a 2.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).